ReShape Medical® Prepares for Market Launch with the Addition of Vice President of Sales Michael N. Moehring

SAN CLEMENTE, Calif., June 3, 2015 /PRNewswire/ -- ReShape Medical® today announced the appointment of Michael N. Moehring as Vice President of Sales. With more than 20 years of medical device sales and sales management experience, Mr. Moehring will help the company prepare for and support US commercialization of the ReShape™ Integrated Dual Balloon System, for which a Premarket Approval (PMA) application was submitted to the US Food and Drug Administration (FDA) mid-2014. ReShape is a next-generation, non-surgical weight loss procedure for people with mild to moderate obesity.

Prior to joining ReShape Medical, Mr. Moehring held numerous executive leadership positions in sales including serving as Vice President of Sales for Pivot Medical, where he successfully built a sales and management team that commercialized a complete platform of hip arthroscopy instruments and implant system. Mr. Moehring played an integral role in Pivot's acquisition by Stryker Corporation and was instrumental in integrating the Pivot Products within the Stryker Sports Medicine Division.

"Mike brings a deep understanding of the medical device market to the team at this critical time for our Company," said Richard Thompson, President and CEO, ReShape Medical. "This addition to our executive team continues the momentum we have established over the past year from our PMA submission through the presentation and publication of our strong pivotal study and international commercial study, and we look forward to working with Mike to help bring our first-of-its-kind dual balloon system to those in need of new weight loss options."

ReShape is a next generation technology with features that are designed to enhance performance in three important areas. First, two connected balloons have a larger fill volume than the older single balloons.  Second, it is designed for greater comfort by mounting the two balloons on a flexible shaft that allows the device to conform to the natural shape of the stomach.  Finally, the ReShape Integrated Dual Balloon is the only intragastric balloon that is designed to prevent the migration of a deflated balloon from the stomach into the intestines where it can lead to an obstruction.

Results from the REDUCE pivotal trial, a randomized, sham control, double blinded study published in the journal Surgery for Obesity and Related Diseases, showed that patients that had the ReShape Procedure lost 2.3 times as much weight as a control group that received diet and exercise coaching only. There were also measurable and sustained improvements in co-morbidities and strong patient satisfaction. The REDUCE trial is the only randomized trial of a weight loss device to successfully meet its endpoints.   In a study of the ReShape Procedure in commercial use in Europe, ReShape patients on average lost 47% of their excess weight at six months and maintained 98% of their weight loss at one year.

About ReShape Medical, Inc.

ReShape Medical, Inc. is a medical device company focused on the development and commercialization of its dual intragastric balloon for weight loss. Driven by a passion to address the worldwide obesity epidemic, the company has developed a non-surgical alternative for obese patients seeking treatment. Additional company information can be found at www.reshapemedical.com. The ReShape Procedure has been available in the European Union since December 2011.

Media Contact:

Wendy Ryan/Rachel Gross 
MSLGROUP 
[email protected] 
781-684-0770

RESHAPE and the RESHAPE MEDICAL Logo are trademarks of ReShape Medical, Inc.

Logo- http://photos.prnewswire.com/prnh/20140630/123304

SOURCE ReShape Medical